Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti–interleukin-17 monoclonal antibody, for psoriasis treatment.
Inflammation, thrombosis, and immunity involve close interactions between leukocytes and vascular endothelium. Endothelial cells represent both targets and producers of lymphokines. Our study was designed to define the capacity of human endothelial cells (HEC) to produce a novel, recently purified, and molecularly cloned monocyte chemotactic and activating factor. This factor has been identified in the culture supernatants of tumor cell lines (tumor-derived chemotactic factor (TDCF)) as well as activated monocytes and fibroblasts (monocyte chemotactic and activating protein, MCAF, or monocyte chemoattractant protein-1, MCP-1). IL-1 induced high levels of production of chemotactic activity for monocytes in culture supernatants of HEC. IL-1-treated HEC expressed high levels of MCAF/MCP-1/TDCF mRNA transcripts, as assessed by Northern blot analysis. TNF and LPS, unlike IL-6, also induced MCAF/MCP-1/TDCF gene expression. Nuclear run off experiments revealed that IL-1-activated transcription of the MCAF/MCP-1/TDCF gene. The production of MCAF/MCP-1/TDCF may represent one of the mechanisms whereby endothelial cells, exposed to inflammatory signals, participate in the regulation of leukocyte extravasation. Production of this cytokine by vascular cells may in particular be relevant under conditions of selective extravasation and activation of mononuclear phagocytes.
1 September 1990 in European Journal of Immunology
A monocyte chemotactic and activating factor (MCAF) has been purified from TNF-stimulated 8387 human fibrosarcoma cell line-conditioned media. The purified MCAF showed microheterogeneity yielding two bands on SDS-PAGE analysis. Fibrosarcoma-derived MCAF specifically competed with THP-1 (a human monocytic cell line)-derived 125I-labeled MCAF in binding to human PBMC, whereas a similar basic heparin-binding leukocyte chemoattractant, IL-8, did not. The purified MCAF stimulated superoxide anion and N-acetyl beta-D glucosaminidase-releasing activity in human monocytes, as well as monocyte cytostatic augmenting activity against tumor cells and chemotactic activity for monocytes. When injected subcutaneously into Lewis rat ears, the purified human MCAF also induced considerable in vivo local monocyte infiltration beginning at 3 h and becoming maximal at 18 h. In conclusion, the data presented in this paper indicate that MCAF is a potent activator of monocytes as well as a monocyte recruitment factor that acts through receptors that are specific for this novel molecule. This novel cytokine might have an important role in tumor growth control due to its ability to attract and activate monocytes.